Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced equity inducement awards for new employees. The company granted a total of 4,510 time-based restricted stock units to 17 new non-executive employees on September 1, 2025.
The awards, approved under Madrigal's 2025 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments. The vesting is contingent upon continued employment through each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL), azienda biofarmaceutica specializzata in terapie per la steatoepatite associata a disfunzione metabolica (MASH), ha comunicato l'assegnazione di incentivi azionari per nuovi dipendenti. In data 1 settembre 2025 la società ha concesso complessivamente 4.510 unità azionarie ristrette basate sul tempo a 17 nuovi dipendenti non dirigenti.
Le assegnazioni, approvate nell'ambito del Piano di Induzione 2025 di Madrigal e conformi alla Regola di quotazione Nasdaq 5635(c)(4), saranno soggette a maturazione in quattro rate annuali uguali, vincolata alla continuazione dell'impiego fino a ciascuna data di maturazione.
Madrigal Pharmaceuticals (NASDAQ:MDGL), una compañía biofarmacéutica especializada en terapias para la esteatohepatitis asociada a disfunción metabólica (MASH), ha anunciado concesiones de incentivos accionariales para nuevos empleados. El 1 de septiembre de 2025 la empresa otorgó en total 4.510 unidades de acciones restringidas basadas en el tiempo a 17 nuevos empleados no ejecutivos.
Las concesiones, aprobadas bajo el Plan de Inducción 2025 de Madrigal y en cumplimiento con la Norma de Cotización de Nasdaq 5635(c)(4), devengarán en cuatro cuotas anuales iguales, condicionadas a la continuidad del empleo hasta cada fecha de devengo.
Madrigal Pharmaceuticals (NASDAQ:MDGL))는 대사 기능 장애 관련 지방간염(MASH) 치료제에 특화된 바이오제약사로, 신입 직원 대상의 주식 인센티브를 발표했습니다. 회사는 2025년 9월 1일자로 17명의 비임원 신입 직원에게 총 4,510주의 시간기반 제한주식(RSU)를 부여했습니다.
이 수여는 Madrigal의 2025 유인 계획(Inducement Plan) 하에 승인되었으며, Nasdaq 상장 규정 5635(c)(4)을 준수합니다. 해당 주식은 동일한 4년의 연간 분할(매년 1/4씩)로 베스팅되며, 각 베스팅일에 근무를 계속하는 경우에만 확정됩니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL), société biopharmaceutique spécialisée dans les traitements de la stéato-hépatite associée à un dysfonctionnement métabolique (MASH), a annoncé des attributions de titres incitatifs pour de nouveaux employés. Le 1er septembre 2025, la société a accordé au total 4 510 unités d'actions restreintes liées au temps à 17 nouveaux employés non dirigeants.
Les attributions, approuvées dans le cadre du Plan d'Incitation 2025 de Madrigal et conformes à la règle de cotation Nasdaq 5635(c)(4), seront acquises selon quatre versements annuels égaux, sous réserve de la poursuite de l'emploi jusqu'à chaque date d'acquisition.
Madrigal Pharmaceuticals (NASDAQ:MDGL), ein biopharmazeutisches Unternehmen, das sich auf Therapien gegen metabolic dysfunction-associated steatohepatitis (MASH) spezialisiert hat, hat Aktienanreize für neue Mitarbeiter bekannt gegeben. Am 1. September 2025 gewährte das Unternehmen insgesamt 4.510 zeitgebundene Restricted Stock Units an 17 neue nicht-exekutive Mitarbeiter.
Die Zuteilungen, genehmigt im Rahmen des Madrigal Inducement Plans 2025 und in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4), werden in vier gleichen jährlichen Tranchen vesten und sind an das Fortbestehen des Arbeitsverhältnisses bis zu den jeweiligen Vesting-Terminen gebunden.
- None.
- None.
CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2025 to 17 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,510 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
How many restricted stock units did Madrigal Pharmaceuticals (MDGL) grant to new employees in September 2025?
What is the vesting schedule for MDGL's September 2025 employee equity awards?
How many new employees received equity awards from Madrigal Pharmaceuticals in September 2025?
Under which plan were Madrigal Pharmaceuticals' September 2025 equity awards granted?
